- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03790982
Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease (WAY)
December 29, 2018 updated by: Zhejiang Hisun Pharmaceutical Co. Ltd.
A Randomized, Double Blind, Placebo Controlled, Parallel-Group 52-week Multicenter Phase II Study to Investigate the Safety, Efficacy and Pharmacokinetics of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease
Brief summary: This is a phase II study to investigate the safety, preliminary efficacy and pharmacokinetics of AD-35 tablet in patients with mild to moderate Alzheimer's Disease.
This study is to be run in China involving 21 sites.
It will enroll approximately 480 patients to ensure 240 randomized with mild to moderate Alzheimer's Disease.
The treatment period is 52 weeks and total study duration per patient is approximately 57 weeks.
Study Overview
Status
Unknown
Conditions
Detailed Description
In this multicenter, randomized, double blind, parallel-group, placebo controlled phase II study, 240 patients with mild to moderate Alzheimer's Disease are planned to be enrolled and randomly assigned 1:1:1 to receive placebo, or different doses of AD-35 tablet (30 or 60 mg).
After the first 26 weeks, subjects on active study drug will remain on the current doses, and subjects assigned to placebo will be randomized to receive 30 mg and 60 mg AD-35 tablet in a 1:1 ratio, respectively, for the second 26 weeks.
This study will evaluate the safety, preliminary efficacy and pharmacokinetics of AD-35 tablets in patients with mild to moderate Alzheimer's Disease.
Study Type
Interventional
Enrollment (Anticipated)
240
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100010
- The Department of Neurosurgery
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women, 50-75 years of age.
- Formal education of five or more years.
- Diagnosed of probable AD in accordance with the NINCDS/ADRDA criteria (2011).
- Mild or moderate AD subjects: MMSE Score of 15-26 and CDR Score ≥ 0.5 (CDR memory score ≥ 0.5).
- Subjects must have a brain magnetic resonance imaging (MRI) scan that is consistent with a clinical diagnosis of probable AD. Brain atrophy and medial temporal lobe atrophy visual assessment scale MTA grading >2 points. Mild white matter degeneration may occur, but Fazekas less than or equal to 2 points and supratentorial lacunar infarction lesions less than or equal to 3 points.
- The total score of modified Hachinski ischemia scale (MHIS) ≤ 4.
- Hamilton depression scale (HAMD) has a total score ≤ 17.
Exclusion Criteria:
- Visual, hearing and verbal communication of subjects cannot meet the needs of cognitive function evaluation.
- Inability to tolerate MRI procedures or contraindication to MRI, (such as implanted in the body, MRI incompatible pacemakers, implantable cardioverter defibrillators, cochlear implants, aneurysm clips, implanted injection pump, implanted nerve stimulator, metallic splinters in the eye, other magnetic, electrical and other metal implants) [note], or any other situation, in the judgment of the Investigator, is not suitable for magnetic resonance imaging (MRI).
- The investigators believe that other severe or unstable conditions may interfere with the cognitive evaluation in clinical trials.
- Dementia caused by other reasons: vascular dementia, central nervous system infection, endocrine system diseases (such as thyroid disease, parathyroid gland disease) and other reasons.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo of AD-35 60mg /AD-35 30mg
Placebo of AD-35 60 mg Placebo of AD-35 30mg x two tablets, once daily in the first 26 weeks (oral), then AD-35 30mg +Placebo of AD-35 30mg, once daily in the second 26 weeks (oral)
|
Placebo 60mg, oral, 1st 26 weeks; AD-35 30mg +Placebo of AD-35 30mg oral 2nd 26 weeks.
Other Names:
|
Placebo Comparator: Placebo of AD-35 60mg /AD-35 60mg
Placebo of AD-35 60 mg Placebo of AD-35 30mg x two tablets, once daily in the first 26 weeks (oral), then AD-35 30mg x two tablets, once daily in the second 26 weeks (oral)
|
Placebo 60mg, oral, 1st 26 weeks; AD-35 60mg oral, 2nd 26 weeks.
Other Names:
|
Experimental: AD-35 30 mg+Placebo of AD-35 30 mg
AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, once daily for 52 weeks (oral)
|
AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, Oral, 52 weeks.
Other Names:
|
Experimental: AD-35 60 mg
AD-35 60 mg AD-35 30 mg× two tablets, once daily for 52 weeks (oral)
|
AD-35 60 mg AD-35 30 mg x two tablets, oral, 52 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) 11 scores
Time Frame: Week 26
|
Changes in the total of ADAS-Cog11 scores of treatment compared with baseline.
The score ranged from 0 to 75, and the higher the score, the greater the cognitive impairment
|
Week 26
|
Changes in Alzheimer's Disease Cooperative Study-clinical global impression of change (ADCS-CGIC ) scores
Time Frame: Week 26
|
Changes in ADCS-CGIC scores of treatment compared with baseline.
The overall condition of the disease change is assessed (improved or deteriorated) by the doctor and the patient, and the 8-point scoring method (0-7 points) was adopted.
|
Week 26
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in ADAS-Cog11 scores
Time Frame: Week 6, week 13, week 39, week52
|
Changes in ADCS-CGIC scores of treatment compared with baseline
|
Week 6, week 13, week 39, week52
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in ADCS-CGIC scores
Time Frame: Week 6, week 13, week 39, week52
|
Changes in ADCS-CGIC scores of treatment compared with baseline
|
Week 6, week 13, week 39, week52
|
Changes in Mini-mental state examination (MMSE) scores
Time Frame: Week 6, week 13, week 26, week 39, week52
|
Changes in MMSE scores of treatment compared with baseline.
Each item has a correct score of 1 and an error score of 0.The total score ranges from 0 to 30, and the normal and abnormal boundary values are related to education degree.
The lower the boundary value was the cognitive impairment, and the above was normal.
|
Week 6, week 13, week 26, week 39, week52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jianping Jia, PhD, Xuanwu hospital, capital medical university, Beijing, China
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2018
Primary Completion (Anticipated)
December 30, 2020
Study Completion (Anticipated)
July 30, 2021
Study Registration Dates
First Submitted
December 18, 2018
First Submitted That Met QC Criteria
December 29, 2018
First Posted (Actual)
January 2, 2019
Study Record Updates
Last Update Posted (Actual)
January 2, 2019
Last Update Submitted That Met QC Criteria
December 29, 2018
Last Verified
December 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AD-35-II-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...RecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsActive, not recruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal CognitionUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
Clinical Trials on Placebo of AD-35 60mg /AD-35 30mg
-
Zhejiang Hisun Pharmaceutical Co. Ltd.Medpace, Inc.UnknownAlzheimer Disease, Early OnsetUnited States
-
Addpharma Inc.Not yet recruitingHypertension,Essential
-
Addpharma Inc.Completed
-
Crucell Holland BVThe PATH Malaria Vaccine Initiative (MVI); Seattle Children's Research Institute...Completed
-
TakedaCompletedDiabetes MellitusJapan
-
Addpharma Inc.CompletedOsteoporosisKorea, Republic of
-
TakedaTerminatedMild Cognitive Impairment Due to Alzheimer's DiseaseUnited States, Australia, United Kingdom, Switzerland
-
TakedaCompleted
-
GlaxoSmithKlineCompletedMultiple SclerosisUnited States, Bulgaria, Russian Federation, Spain, Germany, Czechia, Netherlands, Norway, Italy, Canada, Denmark
-
Korea Otsuka Pharmaceutical Co., Ltd.CompletedPharmacokinetics/Pharmacodynamics (PK/PD) Characteristics of Tolvaptan Tablet in Korean Healthy MaleHealthyKorea, Republic of